skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
VEGFR-2 DNA Vaccine VXM01 (Code C99378)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: VEGFR-2 DNA Vaccine VXM01

Definition: An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature.

Label: VEGFR-2 DNA Vaccine VXM01

NCI Thesaurus Code: C99378 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL433162  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
VEGFR-2 DNA Vaccine VXM01

External Source Codes: 
PDQ Closed Trial Search ID 719728
PDQ Open Trial Search ID 719728 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C99378
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom